EYPT: Strong secondary endpoints and safety drive optimism ahead of the pivotal LUCIA trial
Recent phase III data showed strong safety and reduced treatment burden for wet AMD, despite missing the primary endpoint due to unusual control arm results. The upcoming LUCIA trial will address these findings, with commercial and manufacturing preparations underway and a robust pipeline in diabet…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.